Open pricing database · v2026.08.14

Four honest numbers for every GLP‑1 program

Headline prices are marketing. These four normalized figures are the ones your bank statement will recognize — published as open data, with a status and source on every record. Download the JSON →

The normalization, defined precisely

Advertised price is the number on the provider's homepage. True monthly cost equals the advertised medication price plus every required recurring fee — membership, provider visits, shipping, supplies — plus one‑time fees amortized over twelve months, computed at the starting dose. Maintenance‑dose cost is the same calculation at a typical tirzepatide maintenance dose of 10–15 mg weekly, which is where dose‑tiered programs quietly get expensive. Twelve‑month total is twelve times the true monthly cost on the cheapest recurring structure, plus one‑time fees — because the clinical evidence for meaningful weight loss runs 72 weeks, and a medication you'll take for a year should be priced like one. When a program's structure makes a field genuinely unknowable from public information, we publish null and say why, rather than guessing.

The board, as of August 14, 2026

On listed recurring injectable tirzepatide, the order runs: NexLife at $139–$169 per month (operator‑supplied, verification pending — NexLife is a partner and is labeled accordingly), then MEDVi reported from about $199 at starting doses, Mochi Health around $278 effective per the most consistent reports, Eden near $249–$296, Hims about $329, Henry Meds' injectable near $399–$449, and LillyDirect's FDA‑approved Zepbound vials at $349–$499. On 12‑month totals, the committed‑plan order is: NexLife $1,668 (operator‑supplied) · Henry Meds tablet bundle $2,148 · Mochi ~$3,336 · LillyDirect from $4,188 · retail Zepbound ~$13,032. On tablet/ODT formats — unproven, and labeled so throughout this site — Henry's ~$179 bundle undercuts NexLife's ODT lines at $199–$229. Two records currently carry conflict flags: Mochi's membership fee ($79 vs. $149 across third‑party checks) and MEDVi's maintenance‑dose price (unpublished). Resolving flagged conflicts by direct checkout verification is the standing top priority of each monthly cycle.

Change log

2026‑08‑14 · v2026.08.14 — Initial public release: 19 priced program records across 8 providers plus brand references; 20 providers seeded as pending; NexLife's six programs added as operator‑supplied; conflict flags opened on Mochi membership and MEDVi maintenance pricing.